Cranial electrotherapy stimulation and fibromyalgia.

Gilula MF.

President and Director,
Life Energies Research Institute,
2510 Inagua Avenue, Miami,
FL 33133, USA.
mgilula@mindspring.com.

Cranial electrotherapy stimulation (CES) is a well-documented neuroelectrical modality that has been proven effective in some good studies of fibromyalgia (FM) patients. CES is no panacea but, for some FM patients, the modality can be valuable. This article discusses aspects of both CES and FM and how they relate to the individual with the condition. FM frequently has many comorbidities such as anxiety, depression, insomnia and a great variety of different rheumatologic and neurological symptoms that often resemble multiple sclerosis, dysautonomias, chronic fatigue syndrome and others. However, despite long-standing criteria from the American College of Rheumatology for FM, some physicians believe there is probably no single homogeneous condition that can be labeled as FM. Whether it is a disease, a syndrome or something else, sufferers feel like they are living one disaster after another. Active self-involvement in care usually enhances the therapeutic results of various treatments and also improves the patient’s sense of being in control of the condition. D-ribose supplementation may prove to significantly enhance energy, sleep, mental clarity, pain control and well-being in FM patients. A form of evoked potential biofeedback, the EPFX, is a powerful stress reduction technique which assesses the chief stressors and risk factors for illness that can impede the FM patient’s built-in healing abilities. Future healthcare will likely expand the diagnostic criteria of FM and/or illuminate a group of related conditions and the ways in which the conditions relate to each other. Future medicine for FM and related conditions may increasingly involve multimodality treatment that features CES as one significant part of the therapeutic regimen. Future medicine may also include CES as an invaluable, cost-effective add-on to many facets of clinical pharmacology and medical therapeutics.

PMID: 17605684 [PubMed – in process]

FMS Global News

Tenderpoints

Source

Advertisements

About FMS Global News

Folllowing Rick Usher's death in December 2008, at his request in September of that year, I had agreed, as his principal contributor and an experienced journalist, to run the FMS Global News service due to his heavy commitments to music and raising research funds through this avenue. Following his sad and sudden death I hope to continue his work as he would have wished.
This entry was posted in Boston, Britain, British, CFS, Chronic Fatigue, Chronic Fatigue Syndrome, Chronic Multisymptom Illness, Chronic Pain, Chronic Pain Disorders, Denmark, Dysfunctional Pain Syndrome, Europe, Fatigue, Feeds, Fibrohugs, Fibrohugs News, Fibromyalgia, Fibromyalgia Blogs, Fibromyalgia News, Fibromyalgia News Belgium, Fibromyalgia News Denmark, Fibromyalgia News Deutschland, Fibromyalgia News France, Fibromyalgia News Israel, Fibromyalgia News Italy, Fibromyalgia News Japan, Fibromyalgia News Jerusalem, Fibromyalgia News Korea, Fibromyalgia News Southeast Asia, Fibromyalgia News Turkey, Fibromyalgia News Wisconsin, Fibromyalgia Press Releases, Fibromyalia News Germany, Finland, FMS, FMS Global News, FSS, Functional Somatic Syndrome, Global News, Hypersensitivity, Invisible Illness, Invisible Illnesses, Italy, Japan, Medical, Medical Research, Medical University, Mexico, Mexico City, News, News Australia, News Belgium, News Canada, News Denmark, News France, News India, News Ireland, News Israel, News Italy, News Japan, News Jerusalem, News Korea, News Montreal, News Nigeria, News Norway, News Quebec, News Saskatchewan, News Scotland, News Southeast Asia, News Spain, News Sweden, News Toronto, News Turkey, News UK, News Wisconsin, Nigeria, Non Malignant Chronic Pain, North Carolina, Ontario, Ottawa, Oxford, Pain, Portugal, Seattle, Swedish, Switzerland, Syndromes, Tenderpoints, The Netherlands., Toronto, US, USA, Virginia, Washington DC, World, World News. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s